Technical Analysis for TH - Theratechnologies Inc.

Grade Last Price % Change Price Change
D 2.060 4.04% 0.080
TH closed up 3.13 percent on Wednesday, March 27, 2024, on 1.95 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average.
Earnings due: Apr 10
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 4.04%
Crossed Above 200 DMA Bullish 4.04%
Pocket Pivot Bullish Swing Setup 4.04%
Wide Bands Range Expansion 4.04%
Up 3 Days in a Row Strength 4.04%
Up 4 Days in a Row Strength 4.04%
Up 5 Days in a Row Strength 4.04%
Upper Bollinger Band Touch Strength 4.04%
Gapped Down Weakness 4.04%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.29%

   Recent Intraday Alerts

Alert Time
Upper Bollinger Band Resistance 19 minutes ago
50 DMA Resistance 19 minutes ago
Rose Above 50 DMA about 1 hour ago
Rose Above Upper Bollinger Band about 1 hour ago
Up 5% about 1 hour ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Theratechnologies Inc. Description

Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Drug Medical Specialties IPO Organ Systems Immunology Hiv Infection Rift Antivirals

Is TH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.45
52 Week Low 0.73
Average Volume 36,644
200-Day Moving Average 1.971
50-Day Moving Average 2.064
20-Day Moving Average 1.781
10-Day Moving Average 1.742
Average True Range 0.118
RSI (14) 57.45
ADX 25.8
+DI 30.831
-DI 16.217
Chandelier Exit (Long, 3 ATRs) 1.856
Chandelier Exit (Short, 3 ATRs) 1.974
Upper Bollinger Bands 2.066
Lower Bollinger Band 1.496
Percent B (%b) 0.85
BandWidth 32.027
MACD Line -0.068
MACD Signal Line -0.115
MACD Histogram 0.0468
Fundamentals Value
Market Cap 152.49 Million
Num Shares 77 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -22.25
Price-to-Sales 2.87
Price-to-Book 21.32
PEG Ratio -199.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.325
Resistance 3 (R3) 2.323 2.207 2.268
Resistance 2 (R2) 2.207 2.119 2.208 2.248
Resistance 1 (R1) 2.093 2.065 2.150 2.095 2.229
Pivot Point 1.977 1.977 2.005 1.978 1.977
Support 1 (S1) 1.863 1.889 1.920 1.865 1.731
Support 2 (S2) 1.747 1.835 1.748 1.712
Support 3 (S3) 1.633 1.747 1.693
Support 4 (S4) 1.635